Microbiome diagnostics industry is projected to witness a CAGR of 13.4% during the period 2024-2032. This growth can be attributed to rising demand of personalized medicine.
Selbyville, Delaware, Oct. 29, 2024 (GLOBE NEWSWIRE) --
Microbiome Diagnostics Market size is projected to be worth USD 429.2 million by 2032. Rising innovations in sequencing technologies, including next-generation sequencing (NGS) and metagenomics are enabling comprehensive and detailed analysis of microbiomes whilst improving diagnostic accuracy and providing deeper insights into microbial communities. The integration of microbiome data with genomics, proteomics, and metabolomics is offering a more holistic view of health and diseases.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/9140
Moreover, the surging collaborations between academic institutions, research organizations, and biotechnology companies are making way for advancements in microbiome diagnostics. The growing efforts to leverage complementary expertise and accelerate the development of new diagnostic tools and treatments.
Instruments segment to gain traction
The instruments product segment in the microbiome diagnostics market is likely to register notable growth by 2032. The development of microbiome-based probiotics, prebiotics, and fecal microbiota transplants relies heavily on precise diagnostics to understand the specific strains of microbes involved and their impacts on health, further driving the product demand. The availability of advanced bioinformatics tools and software to analyze large-scale microbiome data has further enhanced the segment progression.
Rising adoption in research applications
Microbiome diagnostics market from the research applications segment is poised to witness a considerable CAGR up to 2032. Microbiome diagnostics assist researchers to understand the role of human microbiome in the development and progression of diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colorectal cancer, obesity, diabetes, and neurological disorders. Researchers are using microbiome profiling to identify specific microbial signatures associated with diseases to assist in the development of potential biomarkers for early diagnosis and treatment.
Asia Pacific to offer lucrative growth opportunities
APAC microbiome diagnostics market size will account for a considerable share by 2032 on account of growing R&D investments especially in countries like China, Japan, and India. Rising awareness among consumers about the role of microbiome in health and wellness is driving the demand for microbiome diagnostics and therapeutics. Surging adoption of microbiome testing in clinical settings for personalized medicine, particularly in gastrointestinal disorders, metabolic diseases, and infectious diseases.